Long term inhibition by Estradiol or Progesterone of Melatonin secretion after administration of a mammary carcinogen, the dimethyl benz(a)anthracene, in Sprague-Dawley female rat; inhibitory effect of Melatonin on mammary carcinogenesis

Breast Cancer Research and Treatment

Volumn 79, Issue 3, 2003, Pages 365-377

  De Jonage Canonico, Marianne Beau Yon ^a   Lenoir, Véronique ^a   Martin, Antoine ^b   Scholler, Robert ^a   Kerdelhué, Bernard ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

DMBA; Estradiol; Female rat; Mammary cancer; Melatonin; Progesterone

Indexed keywords

CARCINOGEN; DIMETHYLBENZ[A]ANTHRACENE; ESTRADIOL; GONADORELIN; ISOPRENALINE; LUTEINIZING HORMONE; MELATONIN; PROGESTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST TUMOR; CONTROLLED STUDY; ESTRUS CYCLE; FEMALE; GONADORELIN RELEASE; HORMONE RELEASE; LATENT PERIOD; LUTEINIZING HORMONE RELEASE; NEUROENDOCRINOLOGY; NONHUMAN; PINEAL BODY; PRIORITY JOURNAL; RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADRENERGIC BETA-AGONISTS; ANIMALS; ANTIOXIDANTS; CARCINOGENS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; ISOPROTERENOL; MAMMARY NEOPLASMS, ANIMAL; MELATONIN; PINEAL GLAND; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0038237060     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024059824430     Document Type: Article

References (45)

1. Huggins C, Grand LC, Brillantes FP: Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature 189: 189-204, 1961
2. Russo J, Tar IK, Russo IH: Differenciation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2(1): 5-73, 1982
3. Russo J, Tait I, Russo IH: Susceptibility of the mammary gland to carcinogenesis. III. The cell of origin of rat mammary carcinogens. Am J Pathol 113(1): 50-66, 1983
4. Daniel FB, Jovco NJ: DNA adduct formation by 7,12-dimethylbenz[a]anthracene and its noncarcinogenic 2-fluoro analog in the female Sprague-Dawley rats. J Natl Cancer Inst 70(1): 111-118, 1983
5. Dao TL: The role of ovarian hormones in initiating the induction of mammary cancer in rats by polynuclear hydrocarbons. Cancer Res 22: 975-981, 1962
6. Kerdelhué B, El Abed A: Inhibition of preovulatory gonadotropin secretion and stimulation of prolactin secretion by 7,12-dimethylbenz[a]anthracene in Sprague-Dawley rats. Cancer Res 39: 4700-4705, 1979
7. El Abed A, Kerdelhué B, Castanier M, Scholler R: Stimulation of estradiol-17β secretion by 7,12-dimethylbenz[a]anthracene during mammary tumor induction in Sprague-Dawley rats. J Steroids Biochem 26: 733-738, 1987
8. Jakubowski M, Lenoir V, Jimenez-Linan M, Duval P, Israel L, Roberts JL, Kerdelhué B: Long-term effects of the mammary carcinogen 7,12-dimethylbenz[a]anthracene on hypothalamic Gonadotropin-Releasing Hormone and its pituitary receptor gene expression, during the promotion stage, in female Sprague-Dawley rats. Breast Cancer Res Treat
9. Kerdelhué B, Peck EJ: In vitro LHRH release: correlation with the LH surge and alteration by a mammary carcinogen. Peptides 2: 219-222, 1981
10. Chang C. Topographic recognition of cyclic hydrocarbons and related compounds by receptors for androgens, estrogens and glucocorticoids. J Steroids Biochem 27(1-3): 123-131, 1987
11. Garcia-Segura LM, Bojda-Diolez F, Lenoir V, Naftolin F, Kerdelhué B: Estrogen-like effects of the mammary carcinogen 7,12-dimethylbenz(a)anthracene upon hypothalamic neuronal membranes. Brain Res Bull 28: 625-628, 1992
12. Pasqualini C, Sarrieau A, Dussalliant M, Corbani M, Diolez-Bojda F, Rostene W, Kerdelhué B: Estrogen-like effects of 7,12-dimethylbenz(a)anthracene on the female rat hypothalamo-pituitary axis. J Steroid Biochem 36: 485-491, 1990
13. Reiter RJ: The pineal gland and its hormones in the control of reproduction in mammals. Endocr Rev 1: 109-131, 1980
14. Vanececk J: Inhibitory effect of melatonin on GnRH-induced LH release. Rev Reproduction 4(2): 67-72, 1999
15. Blask DE, Hill SM, Orstead KM, Massa JS: Inhibition effects of the pineal hormone Melatonin and uderfeeding during the promotional phase of 7,12-DMBA-induced mammary tumorigenesis. J Neural Transm 67(1-2): 125-138, 1986
16. Blask DE, Sauer L, Dauchy R: Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid ametabolims via melatonin receptor-mediated signal transduction events. Cancer Res 59: 4693-4701, 1999
17. Hill SM, Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48: 6121-6126, 1988
18. Cos S, Sanchez-Barcelo EJ: Melatonin reduces the invasion capacity of MCF-7 human breast cancer cells. In vitro studies. Mol Mech Clin Implicat 377-383, 1997
19. Cos S, Fernandez R, Güezmes A, Sanchez-Barcelo EJ: Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58: 4383-4390, 1998
20. Recio J, Cardinali DP, Sanchez-Barcelo EJ: 2-[125I]iodomelatonin binding sites in murine mammary tissue. Biol Signals 3: 85-90, 1994
21. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S: Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13: 857-868, 1999
22. Molis TM, Spriggs LL, Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8: 1681-1690, 1994
23. Danforth DN, Tamarkin L, Lippman ME: Melatonin increases oestrogen receptor binding activity of human breast cancer cells. Nature 305: 323-325, 1983
24. Mediavilla MD, Cos S, Sanchez-Barcelo EJ: Melatonin increases p53 and p21 waf1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 65: 415-420, 1999
25. Cos S, Sanchez-Barcelo EJ: Melatonin and mammary patho-logical growth. Front Neuroendocrinol 21: 133-170, 2000
26. Dural P, Lenoir V, Kerdelhué: The in vitro effect of substance P on the GnRH-induced LH release depends on the steroidal environment and is reverted by a NK1 receptor antagonist (RP67580) in the cycling female rat. Neuropeptides 2: 97-101, 1998
27. Simmoneaux V, Ouichou A, Pevet P, Masson Pevet M, Vivien Roels, Vaudry H: Kinetic study of melatonin release from rat pineal glands using a perifusion technique. J Pineal Res 7(1): 63-83, 1989
28. Ravault JP, Arendt J, Tobler I, Chesneau D, Maulin O: Entrainment of melatonin rhythms in rams by symmetrical dark cycles of different period length. Chronobiol Int 6(4): 329-339, 1989
29. Vacas MI, Keller Sarmiento MI, Pereyra E, Cardinali DP: Early changes in cAMP and melatonin levels of rat pineal gland after superior cervical ganglionectomy. Neuroendocrinol Lett 4(4): 267-271, 1982
30. Cardinali DP, Vacas MI, Keller Sarmiento MI, Etchegoyen GS, Pereyra EN, Chuluyan HE: Neuroendocrine integrative mechanism in mammalian pineal gland: effects of steroid and adenohypophysial hormones on melatonin synthesis in vitro. J Steroid Biochem 27(1-3): 565-571, 1987
31. San Martin M, Touitou Y: Progesterone inhibits, on a circadian basis, the release of melatonin by rat pineal perifusion. Steroids 65(4): 206-209, 2000
32. Ishizuka B, Fusama S, Hirai K, Hosaka T, Hamada N, Amemiya A, Itoh MT: Melatonin secretion from organ-cultured pineal glands of rats: modulation by gonadectomy and gonadotropin-releasing hormone agonist administration. Eur J Endocrinol 142(4): 387-392, 2000
33. Monjir F, Bordon R, Santano C, Abreu P, Hernandez G, Alonso R: Ovarian steroids blocks the isoproterenol-induced elevation of pineal melatonin production in the female rat. Neurosci Lett 119(1): 12-14, 1990
34. Alonso R, Abreu P, Fajardo N, Sanchez Criado JE: Progesterone does not mediate the inhibition of pineal melatonin production during the rat proestrus night. Neurosci Lett 15(2): 150-152, 1993
35. Cardinali DP: Nuclear receptor estrogen complex in the pineal gland. Modulation by sympathetic nerves. Neuroendocrinol 24(5-6): 333-346, 1977
36. Alonso R, Abreu P, Fajardo N, Hernandez Diaz F, Diaz Cruz A, Hernandez G, Sanchez Craido J: Ovarian hormones regulate alpha 1 and beta-adrenoceptor interactions in female rat pinealocytes. Neurorep 6(2): 345-348, 1995
37. MacGuire WL: Estrogen receptor variants in Clinical Breast Cancer. Mol Endocrinol 5(11): 1571-1577, 1991
38. Chaidarun SS, Alexander JM: A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression. Mol Endocrinol 12: 1355-1366, 1998
39. Todorovic R, Ariese F, Devanesan P, Jankowiak R, Small G, Rogan E, Cavalieri E: Determination of benz(a)pyrene- and 7,12-Dimethylbenz(a)anthracene DNA adducts formed in rat mammary gland. Chem Res Toxicol 10: 941-947, 1997
40. Garner R: The role of DNA adducts in chemical carcinogenesis. Murat Res 402: 67-75, 1998
41. Tamarkin L, Cohen M, Roselle D, Reicher C, Lippman M, Chabner B: Melatonin inhibition and pinealectomy enhancement of 7,12-dimethyl-benz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41: 4432-4436, 1981
42. Subramanian A, Kothari LS: Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis. AntiCancer Drugs 2: 297-303, 1991
43. Bartsch C, Bartsch H, Lippert TH, Gupta D: Effect of the mammary carcinogen 7,12-dimethylbenz(a)anthracene on pineal melatonin biosynthesis, secretion and peripheral metabolism. Neuroendocrinology 52(6): 538-544, 1990
44. Tamarkin L, Danforth DN, Lichter A, DeMoss E, Cohen M, Chabner B, Lippman M: Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 216: 1003-1005, 1982
45. Bartsch C, Bartsch H, Bellmann O, Lippert TH: Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 67(6): 1681-1684, 1991